Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 A3 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds of the present invention are useful as inhibitors of aldosterone synthase. The compounds may be used, for example, in the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: A method for realizing backpressure of masses of ports and a device realizing the method are disclosed. The method for realizing backpressure of masses of ports includes: detecting whether user data transmitted to a channelized physical port reaches a backpressure threshold, generating an idle frame or a series of idle frames when the backpressure threshold is reached; combining the idle frame with the user data which needs to be transmitted to the channelized physical port reaching the backpressure threshold, and transmitting the combined data; discarding the idle frame before the combined data enters the channelized physical port. The idle frame is employed in the present invention to realize the backpressure. The idle frame occupies some of the transmission bandwidth and reduces the bandwidth of user data, while the idle frame does not enter the physical port. Therefore, the aim of backpressure is achieved. The bandwidth of idle frame can be pre-configured according to the requirements.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: A method for failure detection on a bidirectional forwarding link mainly includes: sending, by one side of a BFD session, a BFD packet to the opposite side of the BFD session, and detecting a BFD packet sent by the opposite side, and starting, by the local side of the BFD session, BFD session detection when receiving a first BFD packet sent from the opposite side. By the method of the invention, it can be avoided that a router misinforms that failure occurs on a BFD session link due to difference of delays needed to deliver a BFD session parameter from a negotiation module of the router to a detection module.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: A method for failure detection on a bidirectional forwarding link mainly includes: sending, by one side of a BFD session, a BFD packet to the opposite side of the BFD session, and detecting a BFD packet sent by the opposite side, and starting, by the local side of the BFD session, BFD session detection when receiving a first BFD packet sent from the opposite side. By the method of the invention, it can be avoided that a router misinforms that failure occurs on a BFD session link due to difference of delays needed to deliver a BFD session parameter from a negotiation module of the router to a detection module.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: A method for realizing backpressure of masses of ports and a device realizing the method are disclosed. The method for realizing backpressure of masses of ports includes: detecting whether user data transmitted to a channelized physical port reaches a backpressure threshold, generating an idle frame or a series of idle frames when the backpressure threshold is reached; combining the idle frame with the user data which needs to be transmitted to the channelized physical port reaching the backpressure threshold, and transmitting the combined data; discarding the idle frame before the combined data enters the channelized physical port. The idle frame is employed in the present invention to realize the backpressure. The idle frame occupies some of the transmission bandwidth and reduces the bandwidth of user data, while the idle frame does not enter the physical port. Therefore, the aim of backpressure is achieved. The bandwidth of idle frame can be pre-configured according to the requirements.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: The invention is directed to methods to inhibit p38-? kinase using compounds comprising saturated heterocycles coupled to a fused ring system.

Abstract: Piperazine compounds and methods for treating conditions mediated by p38-? kinase are disclosed.

Abstract: Compounds of the formula: wherein the substituents are as defined herein are useful for treating conditions mediated by p38 kinase.

Abstract: The invention is directed to compounds and methods to inhibit p38 kinase wherein the compounds are a pyrimidine or pyridine coupled to two mandatory substituents.

Abstract: The invention is directed to methods to inhibit p38 kinase, preferably p38-? using compounds which are azaindoles wherein the azaindoles are coupled through a piperidine or piperazine type linker to another cyclic moiety.

Abstract: Compounds that inhibit p38-? kinase are those wherein a bicyclic aromatic system is coupled through a saturated ring to an aryl group.

Abstract: The invention is directed to methods to inhibit p38-? kinase using compounds comprising saturated heterocycles coupled to a fused ring system.

Abstract: Compound with an indole linked through an aliphatic ring system to an aromatic moiety are useful in treating conditions associated with enhanced P38? kinase activity.